Such investigations could validate or invalidate the hypothesis that AAA-1 assessment in NAFLD can be used to identify the subset of patients particularly likely to benefit from SGLT-2 inhibition. This evidence concerns the gene NPSR1-AS1 and metabolic dysfunction-associated steatotic liver disease.